The tyrosine kinase inhibitor Imatinib (Gleevec), a well-known inhibitor of the oncogenic Bcr-abl fusion protein, has been used to target the juxtamembrane domain of c-KIT in GIST patients. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.